Palatin Technologies (PTN) Other Working Capital Changes (2019 - 2026)
Palatin Technologies' (PTN) quarterly Other Working Capital Changes came in at -$62126.0 in Q1 2026, up 34.96% YoY from -$46031.9 in Q1 2025, and down 91.89% on a QoQ basis from -$32376.0 in Q4 2025.
Palatin Technologies (PTN) Other Working Capital Changes (2019 - 2026) Analysis & Trends
Palatin Technologies (PTN) has 8 years of Other Working Capital Changes data on file, last reported at -$62126.0 in Q1 2026.
- Quarterly Other Working Capital Changes rose 34.96% year-over-year to -$62126.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$224276.0 (up 39.59% YoY) and the FY2025 annual result came in at -$380543.0, down 7.48% from the prior year.
- Other Working Capital Changes retreated to -$62126.0 in Q1 2026, from -$32376.0 in the prior quarter.
- In the past five years, Other Working Capital Changes ranged from a high of $1.5 million in Q2 2022 to a low of -$1.6 million in Q4 2023.
- A 5-year average of $47324.4 and a median of -$13837.0 in 2024 frame the typical range for Other Working Capital Changes.
- The widest YoY moves for Other Working Capital Changes: up 66.07% in 2025, down 10.39% in 2025.
- Tracing PTN's Other Working Capital Changes over 5 years: stood at -$92947.0 in 2022, then advanced by 6.9% to -$86531.0 in 2023, then decreased by 8.89% to -$94223.0 in 2024, then soared by 65.64% to -$32376.0 in 2025, then plunged by 91.89% to -$62126.0 in 2026.
- The last three Other Working Capital Changes figures came in at -$62126.0 (Q1 2026), -$32376.0 (Q4 2025), and -$31335.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Palatin Technologies | 40.86 Mn | 40.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -62,126.00 |
| Mar 31, 2026 | -62,126.00 |
| Mar 31, 2026 | -62,126.00 |
| Dec 31, 2025 | -32,376.00 |
| Dec 31, 2025 | -32,376.00 |
| Dec 31, 2025 | -32,376.00 |
| Sep 30, 2025 | -31,335.00 |
| Sep 30, 2025 | -31,335.00 |
| Sep 30, 2025 | -31,335.00 |
| Jun 30, 2025 | -98,439.00 |
| Jun 30, 2025 | -98,439.00 |
| Jun 30, 2025 | -98,439.00 |
| Mar 31, 2025 | -95,524.00 |
| Mar 31, 2025 | -95,524.00 |
| Mar 31, 2025 | -95,524.00 |
| Dec 31, 2024 | -94,223.00 |
| Dec 31, 2024 | -94,223.00 |
| Dec 31, 2024 | -94,223.00 |
| Sep 30, 2024 | -92,357.00 |
| Sep 30, 2024 | -92,357.00 |